Skip to content
2000
Volume 25, Issue 14
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

After cisplatin discovery in anticancer treatment, many metals have been studied as potential antitumor agents, especially group IXB elements, such as rhodium, iridium, palladium, and their complexes. The design of polymetallic complexes containing different metal centers with diverse pharmacological characteristics has raised considerable interest in the field of drug development research. This approach aims to exploit the synergistic effect of distinct metal cations, which could contribute to enhancing biological activity. The basic rationale is that the combination of two or more metal ions with the same or different cytotoxic profiles and modes of action may significantly modify the anticancer potential of the resulting complexes, thus enlarging the biological targets and improving the biodistribution properties compared to mononuclear fragments. Among the reported multinuclear anticancer complexes, rhodium-based compounds have attracted considerable attention despite their relatively limited history. The current article presents the results obtained in the field of rhodium complexes, highlighting the recent advances of polynuclear homometallic rhodium compounds as promising antineoplastic candidates. While widespread studies have focused on mononuclear rhodium complexes, the potential of polynuclear Rh-based compounds with structural and functional diversity remains rather understudied. This low interest is most likely due to the typical kinetic inertness and chemical stability of most rhodium complex compounds. These complexes have garnered considerable attention due to their enhanced cytotoxic effects, intracellular distribution, and selectivity, thereby holding promising prospects for the further development of multifunctional drug candidates with desired activity. Recent developments of polynuclear rhodium-based antitumor agents have been summarized in the current review.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575416558250822093008
2025-09-11
2026-02-23

  • From This Site

    /content/journals/mrmc/10.2174/0113895575416558250822093008
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LiY. HuangF. StangP.J. YinS. Supramolecular coordination complexes for synergistic cancer therapy.Acc. Chem. Res.20245781174118710.1021/acs.accounts.4c0003138557015
     [Google Scholar]
  2. WangW. XuY. TangY. LiQ. Self‐assembled metal complexes in biomedical research.Adv. Mater.2025379241612210.1002/adma.20241612239713915
     [Google Scholar]
  3. BaiY. AodengG. GaL. HaiW. AiJ. Research progress of metal anticancer drugs.Pharmaceutics20231512275010.3390/pharmaceutics1512275038140091
     [Google Scholar]
  4. NotaroA. GasserG. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.Chem. Soc. Rev.201746237317733710.1039/C7CS00356K29027562
     [Google Scholar]
  5. LiuP. JiaJ. ZhaoY. WangK.Z. Recent advances on dark and light-activated cytotoxicity of imidazole-containing ruthenium complexes.Mini Rev. Med. Chem.201616427228910.2174/138955751666615112012052426586123
     [Google Scholar]
  6. MaL. LiL. ZhuG. Platinum-containing heterometallic complexes in cancer therapy: Advances and perspectives.Inorg. Chem. Front.20229112424245310.1039/D2QI00205A
     [Google Scholar]
  7. LiX. ZhaoX. WangW. ShiZ. ZhangY. TianQ. YaoY. HeC. DuanC. Biomedical applications of multinuclear Pt(II)/Ru(II)/Ir(III) metallo-supramolecular assemblies for intensive cancer therapy.Coord. Chem. Rev.202349521536610.1016/j.ccr.2023.215366
     [Google Scholar]
  8. CzarnomysyR. RadomskaD. SzewczykO.K. RoszczenkoP. BielawskiK. Platinum and palladium complexes as promising sources for antitumor treatments.Int. J. Mol. Sci.20212215827110.3390/ijms2215827134361037
     [Google Scholar]
  9. SalishchevaO. ProsekovA. Antimicrobial activity of mono- and polynuclear platinum and palladium complexes.Foods and Raw Materials20208229831110.21603/2308‑4057‑2020‑2‑298‑311
     [Google Scholar]
  10. SatapathiS. Polynuclear gold(III) compounds as anticancer agents.Int. J. Adv. Sci. Res.2021124404610.55218/JASR.202112405
     [Google Scholar]
  11. KostovaI. Cytotoxic Organometallic Iridium(III) Complexes.Molecules202530480110.3390/molecules3004080140005112
     [Google Scholar]
  12. KostovaI. Homo- and hetero-multinuclear iridium(III) complexes with cytotoxic activity.Inorganics202513515610.3390/inorganics13050156
     [Google Scholar]
  13. DuChaneC.M. MerolaJ.S. Hexafluoroacetylacetonate (hfac) as ligand for pentamethylcyclopentadienyl (Cp*) rhodium and iridium complexes: Some surprising results, including an Ir3Na1O4 cubane structure.J. Organomet. Chem.202092912155210.1016/j.jorganchem.2020.121552
     [Google Scholar]
  14. AlbaladJ. Carné-SánchezA. GranchaT. Hernández-LópezL. MaspochD. Protection strategies for directionally-controlled synthesis of previously inaccessible metal–organic polyhedra (MOPs): The cases of carboxylate- and amino-functionalised Rh(ii)-MOPs.Chem. Commun. (Camb)20195585127851278810.1039/C9CC07083D31591620
     [Google Scholar]
  15. FurukawaS. HorikeN. KondoM. HijikataY. Carné-SánchezA. LarpentP. LouvainN. DiringS. SatoH. MatsudaR. KawanoR. KitagawaS. Rhodium–organic cuboctahedra as porous solids with strong binding sites.Inorg. Chem.20165521108431084610.1021/acs.inorgchem.6b0209127748586
     [Google Scholar]
  16. FanR. BianM. HuL. LiuW. A new rhodium(I) NHC complex inhibits TrxR: In vitro cytotoxicity and in vivo hepatocellular carcinoma suppression.Eur. J. Med. Chem.201918311172110.1016/j.ejmech.2019.11172131577978
     [Google Scholar]
  17. HussainA. AlajmiM.F. LoneM.A. WaniW.A. Chemistry of rhodium.Therapeutic Rhodium Complexes.ChamSpringer2023111210.1007/978‑3‑031‑35631‑5_2
     [Google Scholar]
  18. MaD.L. WangM. MaoZ. YangC. NgC.T. LeungC.H. Rhodium complexes as therapeutic agents.Dalton Trans.20164572762277110.1039/C5DT04338G26743935
     [Google Scholar]
  19. SamantaS.K. Metal Organic Polygons and Polyhedra: Instabilities and Remedies.Inorganics (Basel)20231113610.3390/inorganics11010036
     [Google Scholar]
  20. HussainA. AlajmiM.F. LoneM.A. WaniW.A. Therapeutic potential of rhodium complexes.Therapeutic Rhodium Complexes.ChamSpringer2023135310.1007/978‑3‑031‑35631‑5_3
     [Google Scholar]
  21. HussainA. AlajmiM.F. LoneM.A. WaniW.A. Mechanism of therapeutic action of rhodium complexes.Therapeutic Rhodium Complexes.ChamSpringer2023556410.1007/978‑3‑031‑35631‑5_4
     [Google Scholar]
  22. SohrabiM. SaeediM. LarijaniB. MahdaviM. Recent advances in biological activities of rhodium complexes: Their applications in drug discovery research.Eur. J. Med. Chem.202121611330810.1016/j.ejmech.2021.11330833713976
     [Google Scholar]
  23. MediciS. PeanaM. NurchiV.M. LachowiczJ.I. CrisponiG. ZorodduM.A. Noble metals in medicine: Latest advances.Coord. Chem. Rev.201528432935010.1016/j.ccr.2014.08.002
     [Google Scholar]
  24. PengY.B. TaoC. TanC.P. ZhaoP. Mitochondrial targeted rhodium(III) complexes: Synthesis, characterized and antitumor mechanism investigation.J. Inorg. Biochem.202121811140010.1016/j.jinorgbio.2021.11140033684684
     [Google Scholar]
  25. WangJ. NieJ.J. GuoP. YanZ. YuB. BuW. Rhodium (I) complex-based polymeric nanomicelles in water exhibiting coexistent near-infrared phosphorescence imaging and anticancer activity in vivo.J. Am. Chem. Soc.202014262709271410.1021/jacs.9b1101331999447
     [Google Scholar]
  26. ZhangJ.J. MuenznerJ.K. Abu el MaatyM.A. KargeB. SchobertR. WölflS. OttI. A multi-target caffeine derived rhodium(i) N-heterocyclic carbene complex: evaluation of the mechanism of action.Dalton Trans.20164533131611316810.1039/C6DT02025A27334935
     [Google Scholar]
  27. Nasiri SovariS. ZobiF. Recent studies on the antimicrobial activity of transition metal complexes of groups 6-12.Chemistry (Basel)20202241845210.3390/chemistry2020026
     [Google Scholar]
  28. MaD.L. HeH.Z. LeungK.H. ChanD.S.H. LeungC.H. Bioactive luminescent transition-metal complexes for biomedical applications.Angew. Chem. Int. Ed.201352307666768210.1002/anie.20120841423765907
     [Google Scholar]
  29. OhataJ. BallZ.T. Rhodium at the chemistry–biology interface.Dalton Trans.20184742148551486010.1039/C8DT03032D30234200
     [Google Scholar]
  30. KatsarosN. AnagnostopoulouA. Rhodium and its compounds as potential agents in cancer treatment.Crit. Rev. Oncol. Hematol.200242329730810.1016/S1040‑8428(01)00222‑012050021
     [Google Scholar]
  31. ZhangW.Y. BridgewaterH.E. BanerjeeS. Soldevila-BarredaJ.J. ClarksonG.J. ShiH. ImbertiC. SadlerP.J. Ligand-controlled reactivity and cytotoxicity of cyclometalated rhodium(III) complexes.Eur. J. Inorg. Chem.2020202011-121052106010.1002/ejic.20190105533776557
     [Google Scholar]
  32. PrathimaT.S. ChoudhuryB. AhmadM.G. ChandaK. BalamuraliM.M. Recent developments on other platinum metal complexes as target-specific anticancer therapeutics.Coord. Chem. Rev.202349021523110.1016/j.ccr.2023.215231
     [Google Scholar]
  33. MandalA. Alternative of cisplatin - Introduction of rhodium analogues.J. Indian Chem. Soc.20241011110138910.1016/j.jics.2024.101389
     [Google Scholar]
  34. ŠtarhaP. DvořákZ. TrávníčekZ. Half-sandwich Ir(III) and Rh(III) 2,2′-dipyridylamine complexes: Synthesis, characterization and in vitro cytotoxicity against the ovarian carcinoma cells.J. Organomet. Chem.201887211412210.1016/j.jorganchem.2018.07.035
     [Google Scholar]
  35. DorcierA. AngW.H. BolañoS. GonsalviL. Juillerat-JeanneratL. LaurenczyG. PeruzziniM. PhillipsA.D. ZanobiniF. DysonP.J. In vitro evaluation of rhodium and osmium RAPTA analogues: The case for organometallic anticancer drugs not based on ruthenium.Organometallics200625174090409610.1021/om060394o
     [Google Scholar]
  36. ScharwitzM.A. OttI. GeldmacherY. GustR. SheldrickW.S. Cytotoxic half-sandwich rhodium(III) complexes: Polypyridyl ligand influence on their DNA binding properties and cellular uptake.J. Organomet. Chem.2008693132299230910.1016/j.jorganchem.2008.04.002
     [Google Scholar]
  37. GulN.S. KhanT-M. LiuY-C. ChoudharyM.I. ChenZ-F. LiangH. Pd(II) and Rh(III) complexes with isoquinoline derivatives induced mitochondriamediated apoptotic and autophagic cell death in HepG2 cells.CCS Chem.2021361626164110.31635/ccschem.020.202000363
     [Google Scholar]
  38. PengY.B. HeW. NiuQ. TaoC. ZhongX.L. TanC.P. ZhaoP. Mitochondria-targeted cyclometalated rhodium(iii) complexes: synthesis, characterization and anticancer research.Dalton Trans.202150269068907510.1039/D1DT01053K34113944
     [Google Scholar]
  39. AliR. AouidaM. Alhaj SulaimanA. MadhusudanS. RamotarD. Can Cisplatin therapy be improved? Pathways that can be targeted.Int. J. Mol. Sci.20222313724110.3390/ijms2313724135806243
     [Google Scholar]
  40. GeldmacherY. OleszakM. SheldrickW.S. Rhodium(III) and iridium(III) complexes as anticancer agents.Inorg. Chim. Acta20123938410210.1016/j.ica.2012.06.046
     [Google Scholar]
  41. KomorA.C. SchneiderC.J. WeidmannA.G. BartonJ.K. Cell-selective biological activity of rhodium metalloinsertors correlates with subcellular localization.J. Am. Chem. Soc.201213446192231923310.1021/ja309068723137296
     [Google Scholar]
  42. ErnstR.J. KomorA.C. BartonJ.K. Selective cytotoxicity of rhodium metalloinsertors in mismatch repair-deficient cells.Biochemistry20115050109191092810.1021/bi201582222103240
     [Google Scholar]
  43. HackenbergF. OehningerL. AlborziniaH. CanS. KitanovicI. GeldmacherY. KokoschkaM. WölflS. OttI. SheldrickW.S. Highly cytotoxic substitutionally inert rhodium(III) tris(chelate) complexes: DNA binding modes and biological impact on human cancer cells.J. Inorg. Biochem.2011105799199910.1016/j.jinorgbio.2011.04.00621569751
     [Google Scholar]
  44. López-HernándezJ.E. ContelM. Promising heterometallic compounds as anticancer agents: Recent studies in vivo.Curr. Opin. Chem. Biol.20237210225010.1016/j.cbpa.2022.10225036566618
     [Google Scholar]
  45. KostovaI. Recent developments in antitumor activity of organometallic rhodium complex compounds with macrocyclic ligands.Anticancer Potential of Macrocyclic Metal Complexes.ACS Publications202519723310.1021/bk‑2025‑1492.ch009
     [Google Scholar]
  46. MálikováK. MasarykL. ŠtarhaP. Anticancer half-sandwich rhodium (III) complexes.Inorganics2021942610.3390/inorganics9040026
     [Google Scholar]
  47. GuptaG. Mahesh KumarJ. GarciA. RangarajN. NageshN. TherrienB. Anticancer activity of half‐sandwich Rh III and Ir III metalla‐prisms containing lipophilic side chains.ChemPlusChem201479461061810.1002/cplu.20130042531986703
     [Google Scholar]
  48. ParveenS. HanifM. LeungE. TongK.K.H. YangA. AstinJ. De ZoysaG.H. SteelT.R. GoodmanD. MovassaghiS. SöhnelT. SarojiniV. JamiesonS.M.F. HartingerC.G. Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity.Chem. Commun. (Camb)20195580120161201910.1039/C9CC03822A31498360
     [Google Scholar]
  49. GuptaG. KumarJ. GarciA. NageshN. TherrienB. Exploiting natural products to build metalla-assemblies: The anticancer activity of embelin-derived Rh(III) and Ir(III) metalla-rectangles.Molecules20141956031604610.3390/molecules1905603124824137
     [Google Scholar]
  50. GuptaG. OgguG.S. NageshN. BokaraK.K. TherrienB. Anticancer activity of large metalla-assemblies built from half-sandwich complexes.CrystEngComm201618264952495710.1039/C6CE00139D
     [Google Scholar]
  51. FurrerJ. Süss-FinkG. Thiolato-bridged dinuclear arene ruthenium complexes and their potential as anticancer drugs.Coord. Chem. Rev.2016309365010.1016/j.ccr.2015.10.007
     [Google Scholar]
  52. GuptaG. GarciA. MurrayB.S. DysonP.J. FabreG. TrouillasP. GianniniF. FurrerJ. Süss-FinkG. TherrienB. Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(iii) and Ir(iii) complexes.Dalton Trans.20134243154571546310.1039/c3dt51991k24022745
     [Google Scholar]
  53. JohnpeterJ.P. GuptaG. KumarJ.M. SrinivasG. NageshN. TherrienB. Biological studies of chalcogenolato-bridged dinuclear half-sandwich complexes.Inorg. Chem.20135223136631367310.1021/ic402230724245963
     [Google Scholar]
  54. GuptaG. MurrayB.S. DysonP.J. TherrienB. Highly cytotoxic trithiolato-bridged dinuclear Rh(III) and Ir(III) complexes.J. Organomet. Chem.2014767788210.1016/j.jorganchem.2014.05.021
     [Google Scholar]
  55. KataokaY. YanoN. MikuriyaM. HandaM. Coordination polymers and metal–organic frameworks based on paddlewheel-type dirhodium(II) tetracarboxylates.Coord. Chem. Rev.202247221479610.1016/j.ccr.2022.214796
     [Google Scholar]
  56. EspósitoB.P. OliveiraE. ZyngierS.B. NajjarR. Effects of human serun albumin in some biological properties of rhodium(II) complexes.J. Braz. Chem. Soc.200011544745210.1590/S0103‑50532000000500003
     [Google Scholar]
  57. ReibscheidE.M. ZyngierS. MariaD.A. MistroneR.J. SinisterraR.D. CoutoL.G. NajjarR. Antitumor effects of rhodium (II) complexes on mice bearing Ehrlich tumors.Braz. J. Med. Biol. Res.19942719194[PMID: 8173534
     [Google Scholar]
  58. HowardR.A. KimballA.P. BearJ.L. Mechanism of action of tetra-mu-carboxylatodirhodium(II) in L1210 tumor suspension culture.Cancer Res.1979397 Pt 125682573[PMID: 445459
     [Google Scholar]
  59. LoretoD. FerraroG. MerlinoA. Unusual structural features in the adduct of dirhodium tetraacetate with lysozyme.Int. J. Mol. Sci.2021223149610.3390/ijms2203149633540880
     [Google Scholar]
  60. Enriquez GarciaA. JalilehvandF. NiksiratP. Reactions of Rh 2 (CH3 COO)4 with thiols and thiolates: A structural study.J. Synchrotron Radiat.201926245046110.1107/S160057751900033X30855255
     [Google Scholar]
  61. Enriquez GarciaA. JalilehvandF. NiksiratP. GelfandB.S. Methionine binding to dirhodium (II) tetraacetate.Inorg. Chem.20185720127871279910.1021/acs.inorgchem.8b0197930247895
     [Google Scholar]
  62. PoppB.V. ChenZ. BallZ.T. Sequence-specific inhibition of a designed metallopeptide catalyst.Chem. Commun.201248607492749410.1039/c2cc33808d22728748
     [Google Scholar]
  63. WongD.L. StillmanM.J. Metallothionein: An aggressive scavenger- The metabolism of rhodium(II) tetraacetate (Rh2(CH3CO2)4).ACS Omega2018311163141632710.1021/acsomega.8b0216131458267
     [Google Scholar]
  64. VohidovF. CoughlinJ.M. BallZ.T. Rhodium(II) metallopeptide catalyst design enables fine control in selective functionalization of natural SH3 domains.Angew. Chem. Int. Ed.201554154587459110.1002/anie.20141174525688989
     [Google Scholar]
  65. MinusM.B. KangM.K. KnudsenS.E. LiuW. KruegerM.J. SmithM.L. RedellM.S. BallZ.T. Assessing the intracellular fate of rhodium(ii) complexes.Chem. Commun. (Camb)20165278116851168810.1039/C6CC05192H27709185
     [Google Scholar]
  66. ChevalleyA. CherrierM.V. Fontecilla-CampsJ.C. GhasemiM. SalmainM. Artificial metalloenzymes derived from bovine β-lactoglobulin for the asymmetric transfer hydrogenation of an aryl ketone – Synthesis, characterization and catalytic activity.Dalton Trans.201443145482548910.1039/C3DT53253D24531201
     [Google Scholar]
  67. LoretoD. MerlinoA. The interaction of rhodium compounds with proteins: A structural overview.Coord. Chem. Rev.202144221399910.1016/j.ccr.2021.213999
     [Google Scholar]
  68. TolbatovI. MarroneA. Reaction of dirhodium and diruthenium paddlewheel tetraacetate complexes with nucleophilic protein sites: A computational study.Inorg. Chim. Acta202253012068410.1016/j.ica.2021.120684
     [Google Scholar]
  69. GuptaR.K. PandeyR. SharmaG. PrasadR. KochB. SrikrishnaS. LiP.Z. XuQ. PandeyD.S. DNA binding and anti-cancer activity of redox-active heteroleptic piano-stool Ru(II), Rh(III), and Ir(III) complexes containing 4-(2-methoxypyridyl)phenyldipyrromethene.Inorg. Chem.20135273687369810.1021/ic302196v23477351
     [Google Scholar]
  70. AguirreJ.D. Angeles-BozaA.M. ChouaiA. TurroC. PelloisJ.P. DunbarK.R. Anticancer activity of heteroleptic diimine complexes of dirhodium: A study of intercalating properties, hydrophobicity and in cellulo activity.Dalton Trans.20094848108061081210.1039/b915357h20023910
     [Google Scholar]
  71. JoyceL.E. AguirreJ.D. Angeles-BozaA.M. ChouaiA. FuP.K.L. DunbarK.R. TurroC. Photophysical properties, DNA photocleavage, and photocytotoxicity of a series of dppn dirhodium(II,II) complexes.Inorg. Chem.201049125371537610.1021/ic100588d20496907
     [Google Scholar]
  72. Ali NazifM. BangertJ.A. OttI. GustR. StollR. SheldrickW.S. Dinuclear organoiridium(III) mono- and bis-intercalators with rigid bridging ligands: Synthesis, cytotoxicity and DNA binding.J. Inorg. Biochem.2009103101405141410.1016/j.jinorgbio.2009.08.00319744736
     [Google Scholar]
  73. HrdinaR. Dirhodium (II, II) paddlewheel complexes.Eur. J. Inorg. Chem.20212021650152810.1002/ejic.202000955
     [Google Scholar]
  74. ErnstR.J. SongH. BartonJ.K. DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors.J. Am. Chem. Soc.200913162359236610.1021/ja808104419175313
     [Google Scholar]
  75. ChifotidesH.T. DunbarK.R. Rhodium compounds.Multiple Bonds Between Metal Atoms. CottonF.A. MurilloC. WaltonR.A. New YorkSpringer-Science and Business Media Inc.200546558910.1007/0‑387‑25829‑9_12
     [Google Scholar]
  76. ZyngierS. KimuraE. NajjarR. Antitumor effects of rhodium (II) citrate in mice bearing Ehrlich tumors.Braz. J. Med. Biol. Res.1989223397401[PMID: 2804473
     [Google Scholar]
  77. MilutinovićM.M. BogojeskiJ.V. KlisurićO. ScheurerA. ElmrothS.K.C. BugarčićŽ.D. Synthesis and structures of a pincer-type rhodium(iii) complex: Reactivity toward biomolecules.Dalton Trans.20164539154811549110.1039/C6DT02772E27722449
     [Google Scholar]
  78. ChifotidesH.T. FuP.K.L. DunbarK.R. TurroC. Effect of equatorial ligands of dirhodium(II,II) complexes on the efficiency and mechanism of transcription inhibition in vitro.Inorg. Chem.20044331175118310.1021/ic034438m14753842
     [Google Scholar]
  79. BieńM. PruchnikF.P. SeniukA. LachowiczT.M. JakimowiczP. Studies of antibacterial activity of binuclear rhodium (II) complexes with heterocyclic nitrogen ligands.J. Inorg. Biochem.1999731-2495510.1016/S0162‑0134(98)10090‑910212994
     [Google Scholar]
  80. AguirreJ.D. Angeles-BozaA.M. ChouaiA. PelloisJ.P. TurroC. DunbarK.R. Live cell cytotoxicity studies: documentation of the interactions of antitumor active dirhodium compounds with nuclear DNA.J. Am. Chem. Soc.200913132113531136010.1021/ja902171719624128
     [Google Scholar]
  81. SorasaeneeK. FuP.K.L. Angeles-BozaA.M. DunbarK.R. TurroC. Inhibition of transcription in vitro by anticancer active dirhodium(II) complexes.Inorg. Chem.20034241267127110.1021/ic020591p12588165
     [Google Scholar]
  82. SiuF.M. LinI.W.S. YanK. LokC.N. LowK.H. LeungT.Y.C. LamT-L. CheC-M. Anticancer dirhodium(ii,ii) carboxylates as potent inhibitors of ubiquitin-proteasome system.Chem. Sci.201236178510.1039/c2sc00620k
     [Google Scholar]
  83. FerraroG. PratesiA. MessoriL. MerlinoA. Protein interactions of dirhodium tetraacetate: a structural study.Dalton Trans.20204982412241610.1039/C9DT04819G32022076
     [Google Scholar]
  84. LoretoD. FasuloF. Muñoz-GarcíaA.B. PavoneM. MerlinoA. Unexpected imidazole coordination to the dirhodium center in a protein environment: Insights from X-ray crystallography and quantum chemistry.Inorg. Chem.202261228402840510.1021/acs.inorgchem.2c0137035609175
     [Google Scholar]
  85. LoretoD. EspositoA. DemitriN. GuaragnaA. MerlinoA. Reactivity of a fluorine-containing dirhodium tetracarboxylate compound with proteins.Dalton Trans.20225193695370510.1039/D2DT00082B35166290
     [Google Scholar]
  86. JalilehvandF. Enriquez GarciaA. NiksiratP. FinfrockY.Z. GelfandB.S. Binding of histidine and human serum albumin to dirhodium(II) tetraacetate.J. Inorg. Biochem.202122411155610.1016/j.jinorgbio.2021.11155634425475
     [Google Scholar]
  87. TolbatovI. UmariP. MarroneA. The binding of diruthenium (II,III) and dirhodium (II,II) paddlewheel complexes at DNA/RNA nucleobases: Computational evidences of an appreciable selectivity toward the AU base pairs.J. Mol. Graph. Model.202413110880610.1016/j.jmgm.2024.10880638824876
     [Google Scholar]
  88. LoretoD. EspositoA. DemitriN. GuaragnaA. MerlinoA. Digging into protein metalation differences triggered by fluorine containing-dirhodium tetracarboxylate analogues.Dalton Trans.202251187294730410.1039/D2DT00873D35482032
     [Google Scholar]
  89. Amo-OchoaP. CastilloO. HarringtonR.W. ZamoraF. HoultonA. Substituent and noncovalent interaction effects in the reactivity of purine derivatives with tetracarboxylato-dirhodium(II) units. Rationalization of a rare binding mode via N3.Inorg. Chem.20135242174218110.1021/ic302602c23373427
     [Google Scholar]
  90. RubinJ.R. HaromyT.P. SundaralingamM. Structure of the anti-cancer drug complex tetrakis(μ-acetato)-bis(1-methylade-nosine)dirhodium(II) monohydrate.Acta Crystallogr. C19914781712171410.1107/S010827019100032X1781962
     [Google Scholar]
  91. ChifotidesH.T. DunbarK.R. Unprecedented head-to-head right-handed cross-links between the antitumor bis(μ-N,N′-di-p-tolylformamidinate) dirhodium(II,II) core and the dinucleotide d(ApA) with the adenine bases in the rare imino form.J. Am. Chem. Soc.200712941124801249010.1021/ja073422i17883272
     [Google Scholar]
  92. PalmerA.M. KnollJ.D. TurroC. Photoinduced interactions of two dirhodium complexes with d(GTCGAC)2 probed by 2D NOESY.Dalton Trans.20154483640364610.1039/C4DT03119A25557067
     [Google Scholar]
  93. ChifotidesH.T. KoomenJ.M. KangM. TichyS.E. DunbarK.R. RussellD.H. Binding of DNA purine sites to dirhodium compounds probed by mass spectrometry.Inorg. Chem.200443206177618710.1021/ic040040u15446862
     [Google Scholar]
  94. TitoG. TroisiR. FerraroG. GeriA. MassaiL. MessoriL. SicaF. MerlinoA. Dirhodium tetraacetate binding to a B-DNA double helical dodecamer probed by X-ray crystallography and mass spectrometry.Dalton Trans.202352216992699610.1039/D3DT00320E37199244
     [Google Scholar]
  95. TolbatovI. MarroneA. Kinetics of reactions of dirhodium and diruthenium paddlewheel tetraacetate complexes with nucleophilic protein sites: Computational Insights.Inorg. Chem.20226141164211642910.1021/acs.inorgchem.2c0251636194651
     [Google Scholar]
  96. FandzlochM. AugustyniakA.W. DobrzańskaL. JędrzejewskiT. SitkowskiJ. WypijM. GolińskaP. First dinuclear rhodium(II) complexes with triazolopyrimidines and the prospect of their potential biological use.J. Inorg. Biochem.202021011107210.1016/j.jinorgbio.2020.11107232563102
     [Google Scholar]
  97. PyatakovD.A. SokolovA.N. AstakhovA.V. ChernenkoA.Y. FakhrutdinovA.N. RybakovV.B. ChernyshevV.V. ChernyshevV.M. Diversity oriented synthesis of polycyclic heterocycles through the condensation of 2-amino[1,2,4] triazolo[1,5- a]pyrimidines with 1,3-diketones.J. Org. Chem.20158021106941070910.1021/acs.joc.5b0190826426734
     [Google Scholar]
  98. Gamal-EldeenA.M. HamdyN.A. Abdel-AzizH.A. El-HussienyE.A. FakhrI.M.I. Induction of intrinsic apoptosis pathway in colon cancer HCT-116 cells by novel 2-substituted-5,6,7,8-tetrahydronaphthalene derivatives.Eur. J. Med. Chem.20147732333310.1016/j.ejmech.2014.03.02124657569
     [Google Scholar]
  99. GomhaS.M. EldebssT.M.A. AbdullaM.M. MayhoubA.S. Diphenylpyrroles: Novel p53 activators.Eur. J. Med. Chem.20148247247910.1016/j.ejmech.2014.05.08224934571
     [Google Scholar]
  100. FandzlochM. DobrzańskaL. JędrzejewskiT. JezierskaJ. WiśniewskaJ. ŁakomskaI. Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.J. Biol. Inorg. Chem.202025110912410.1007/s00775‑019‑01743‑531741123
     [Google Scholar]
  101. FandzlochM. JarominA. Zaremba-CzogallaM. WojtczakA. LewińskaA. SitkowskiJ. WiśniewskaJ. ŁakomskaI. GubernatorJ. Nanoencapsulation of a ruthenium(ii) complex with triazolopyrimidine in liposomes as a tool for improving its anticancer activity against melanoma cell lines.Dalton Trans.20204941207121910.1039/C9DT03464A31903475
     [Google Scholar]
  102. A, B.P.R.; A, U.; T, C.; Bethu, M.S.; J, V.R.; Deb, D.K.; Sarkar, B.; Kaminsky, W.; Kollipara, M.R. The in vitro antitumor activity of oligonuclear polypyridyl rhodium and iridium complexes against cancer cells and human pathogens.J. Organomet. Chem.201682413113910.1016/j.jorganchem.2016.10.018
     [Google Scholar]
  103. SuddingL.C. PayneR. GovenderP. EdafeF. ClavelC.M. DysonP.J. TherrienB. SmithG.S. Evaluation of the in vitro anticancer activity of cyclometalated half-sandwich rhodium and iridium complexes coordinated to naphthaldimine-based poly(propyleneimine) dendritic scaffolds.J. Organomet. Chem.2014774798510.1016/j.jorganchem.2014.10.003
     [Google Scholar]
  104. BurgoyneA.R. KaschulaC.H. ParkerM.I. SmithG.S. In vitro Cytotoxicity of Half‐Sandwich Platinum Group Metal Complexes of a Cationic Alkylated Phosphaadamantane Ligand.Eur. J. Inorg. Chem.2016201681267127310.1002/ejic.201501458
     [Google Scholar]
  105. ChellanP. LandK.M. ShokarA. AuA. AnS.H. TaylorD. SmithP.J. RiedelT. DysonP.J. ChibaleK. SmithG.S. Synthesis and evaluation of new polynuclear organometallic Ru(ii), Rh(ii) and Ir(iii) pyridyl ester complexes as in vitro antiparasitic and antitumor agents.Dalton Trans.201443251352610.1039/C3DT52090K24121555
     [Google Scholar]
  106. BurgoyneA.R. MakhubelaB.C.E. MeyerM. SmithG.S. Trinuclear Half‐Sandwich RuII, RhIII and IrIII Polyester Organometallic Complexes: Synthesis and in vitro Evaluation as Antitumor Agents.Eur. J. Inorg. Chem.2015201581433144410.1002/ejic.201403192
     [Google Scholar]
  107. SteelT.R. TongK.K.H. SöhnelT. JamiesonS.M.F. WrightL.J. CrowleyJ.D. HanifM. HartingerC.G. Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity.Inorg. Chim. Acta202151812022010.1016/j.ica.2020.120220
     [Google Scholar]
/content/journals/mrmc/10.2174/0113895575416558250822093008
Loading
Homometallic Polynuclear Rhodium Complexes in Anticancer Drug Development
Mini Rev Med Chem 25, 1114 (2025); https://doi.org/10.2174/0113895575416558250822093008
/content/journals/mrmc/10.2174/0113895575416558250822093008
/content/journals/mrmc/10.2174/0113895575416558250822093008
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): anticancer; complexes; drug development; homometallic; polynuclear; Rhodium

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test